Avaii Wealth Management LLC bought a new position in Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 22,336 shares of the company's stock, valued at approximately $2,652,000. Moderna accounts for 1.5% of Avaii Wealth Management LLC's holdings, making the stock its 18th biggest holding.
Other hedge funds have also made changes to their positions in the company. Mission Wealth Management LP purchased a new stake in shares of Moderna during the 4th quarter worth $205,000. Hexagon Capital Partners LLC lifted its stake in shares of Moderna by 182.4% during the 4th quarter. Hexagon Capital Partners LLC now owns 610 shares of the company's stock worth $61,000 after purchasing an additional 394 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Moderna by 7.5% during the 4th quarter. Victory Capital Management Inc. now owns 303,132 shares of the company's stock worth $30,146,000 after purchasing an additional 21,135 shares during the last quarter. First Trust Direct Indexing L.P. purchased a new stake in shares of Moderna during the 4th quarter worth $372,000. Finally, Fisher Asset Management LLC purchased a new stake in shares of Moderna during the 4th quarter worth $227,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on MRNA. JPMorgan Chase & Co. reduced their target price on Moderna from $96.00 to $88.00 and set a "neutral" rating on the stock in a research report on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised Moderna from a "sell" rating to a "hold" rating and reduced their target price for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Evercore ISI reaffirmed an "in-line" rating and set a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Hsbc Global Res raised Moderna from a "moderate sell" rating to a "hold" rating in a research report on Wednesday. Finally, Oppenheimer upped their target price on Moderna from $163.00 to $179.00 and gave the company an "outperform" rating in a research report on Wednesday, June 12th. Ten equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $123.79.
Check Out Our Latest Stock Analysis on Moderna
Insiders Place Their Bets
In other news, Director Noubar Afeyan sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $151.25, for a total value of $2,268,750.00. Following the transaction, the director now owns 1,946,931 shares in the company, valued at $294,473,313.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Noubar Afeyan sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $151.25, for a total value of $2,268,750.00. Following the transaction, the director now owns 1,946,931 shares in the company, valued at $294,473,313.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James M. Mock sold 1,321 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 330,736 shares of company stock worth $46,330,112. 15.70% of the stock is owned by corporate insiders.
Moderna Price Performance
MRNA stock traded down $0.19 during mid-day trading on Friday, reaching $77.40. 3,591,705 shares of the company's stock were exchanged, compared to its average volume of 4,083,584. The company has a market cap of $29.66 billion, a price-to-earnings ratio of -4.94 and a beta of 1.67. The stock's 50 day moving average is $104.62 and its 200 day moving average is $112.99. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47.
Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. Moderna's revenue for the quarter was down 29.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($3.62) earnings per share. On average, research analysts expect that Moderna, Inc. will post -7.46 EPS for the current year.
Moderna Profile
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
